No images? Click here
9 December 2022
New data presented in the 2022 edition of the World malaria report show that countries around the world largely held the line against further setbacks to malaria prevention, testing and treatment services in 2021. However, a convergence of threats continues to undermine efforts to control the disease, particularly in the African Region.
Full report | Press release | Global briefing kit | Regional briefing kit
This year’s report includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets. How serious are these threats, and what can be done to preserve their effectiveness? Dr Abdisalan Noor, lead author of the report, shares his insights on these and other topics.
The new dashboard provides an overview of all malaria vaccines in clinical development. The interactive page features information on WHO review status, target malaria species, life cycle stage, vaccine platform, target antigen, and adjuvants. It also includes information on clinical trials, indicating trial sites by country and controlled human malaria infection studies.
The WHO Global Malaria Programme is developing a series of preferred product characteristics (PPCs) to encourage further innovation in malaria prevention and control. These draft PPCs posted for public consultation describe the preferred characteristics of vector control products developed with the aim of controlling outdoor malaria transmission.
WHO has published updated recommendations on the use of artesunate and pyronaridine; the use of artemether-lumefantrine for the treatment of uncomplicated malaria in the first trimester of pregnancy; and the use of a one-week course of primaquine as anti-relapse treatment for P. vivax malaria.
The recommendations have been published in the consolidated WHO guidelines for malaria on MAGICapp.
WHO has published the latest meeting report of the Malaria Policy Advisory Group (MPAG), the Organization’s top-level advisory body on malaria. The meeting, held on 11–13 October, covered updates across a range of technical areas, such as the “High burden to high impact” (HBHI) approach, the RTS,S malaria vaccine roll-out and a new framework to respond to malaria in urban areas.
